Wendy Carter, DO
Medical Officer
Division of Antiviral Products, FDA

Click to view Biosketch and Presentation Abstract
or page down to review presentation
Evaluation of Transaminase Elevations in Subjects with Chronic Hepatitis C

Wendy Carter, DO
Medical Officer
Division of Antiviral Products, FDA

The opinions expressed by Dr. Carter in this presentation do not reflect official support or endorsement by the US Food and Drug Administration.
Determining DILI due to HCV DAA Therapy: Challenges

• Definitions used in non-HCV populations may not apply (Hy’s Law)

• Liver biochemistries generally improve with DAA therapy
  • Should changes be evaluated from traditional x ULN, or baseline or nadir?

• Presentations vary based on multiple factors
  – Comorbidities, concomitant medications, stage of liver disease, host genetic factors etc.
Definitions and Management

• FDA DILI Guidance and Hy’s Law
  – Not intended for patients with chronic HCV
  – Updates to guidance are in process
• What is the type of injury?
  – Immune related
  – Cholestatic
  – Drug-Drug interaction
• What discontinuation and follow-up criteria are appropriate in this population?
  • Based on what cut-offs?
  • Balance between safety and not having early discontinuation with loss of efficacy
Use of Multiple Investigational Agents

- Use of several unapproved products in a regimen makes attribution more difficult
  - Totality of data
  - Consideration of class
    - Protease inhibitors for treatment of HIV are known to have risk of hepatotoxicity
- What host factors are an issue?
  - Stage of disease; genetic predisposition, immune response to clearing of the virus (different without use of pegINF?)
Drug-Induced Immunoallergic Hepatitis During Combination Therapy With Daclatasvir and Asunaprevir

Yohei Fujii, Yoshihito Uchida, and Satoshi Mochida

- Daclatasvir (DCV) – NS5A inhibitor
- Asunaprevir (ASV) – NS3/4A protease inhibitor
- Approved in Japan in combination for treatment of chronic hepatitis C

Hepatology. 2015 Jan;61(1):400-1.
DCV/ASV Immunoallergic Hepatitis Case Report

• 57 year old male with GT1b CHC on a planned 24 week treatment with daclatasvir (DCV) and asunaprevir (ASV)
• At Day 15, developed fever and eosinophilia, ALT was normal and HCV RNA decreased to 50 IU/mL from 12.6 million IU/mL
• At Day 29: ALT was 609 U/L, Alk P 320 U/L and bilirubin 3.3 mg/dL and further increase in eosinophilia to 2,876 mm3 ; DCV and ASV were stopped
• Day 36 liver biopsy: interface hepatitis with bridging fibrosis and focal lobular necrosis with eosinophils, lymphocytes and plasma cells in the hepatic lobules and portal areas.
• Day 37 prednisone taper started with rapid resolution of liver biochemistry abnormalities

Hepatology. 2015 Jan;61(1):400-1.
Fig. 1. Clinical course of a patient with immunoallergic liver injury during therapy with daclatasvir and asunaprevir.

Hepatology. 2015 Jan;61(1):400-1.
Genetic Component to Syndrome and/or DILI?

• Authors state overall clinical syndrome was typical of drug fever or drug-hypersensitivity syndrome rather than DRESS (drug rash with eosinophilia and systemic signs)

• In the Japanese DCV/ASV trial, 16% of subjects had ALT elevations and 9% had ALT above 5x ULN
  – This syndrome as well as ALT elevations/fever appeared more frequently in Japanese than in US/EU trials

• Authors suggest genetic basis for liver findings

Hepatology. 2015 Jan;61(1):400-1.
Impact of Stage of Disease

• Unknown how more advanced disease states of CHC may respond to many of the new DAA regimens
• Few have large safety databases of more advanced cirrhotic subjects at approval
• More advanced patients are also in most need for treatment
• Leads to compassionate use
Sofosbuvir and Simeprevir

- Sofosbuvir (nucleotide analog NS5B polymerase inhibitor) and simeprevir (NS3/4A protease inhibitor)
- Recommended as an option in treatment guidelines (off label) prior to approval of this regimen on November 5, 2014
- Was often used in patients with advanced disease and limited pegINF/RBV free treatment options
  - Simeprevir label: not recommended for severe hepatic impairment (Child-Pugh Class C)
Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis

Jonathan G. Stine · Nicolas Intagliata · Neeral L. Shah · Curtis K. Argo · Stephen H. Caldwell · James H. Lewis · Patrick G. Northup

- 2 case reports of DILI leading to hepatic decompensation in patients with advanced HCV cirrhosis treated with Simeprevir and Sofosbuvir on a compassionate basis.
- Both patients developed marked hyperbilirubinemia out of proportion to their aminotransferases, despite clearance of HCV RNA.
- Authors point to possible impaired metabolism from under-expression of hepatic transporters OATP1B1 and MRP2, which are known to be reduced in advance liver disease and cirrhosis.
- Authors argue that SMV be used with great caution, if at all, in CPT Class B or C patients (await newer DAAs- NS5As are referenced)
• Approved December 19, 2014
• Ombitasvir (NS5A inhibitor), paritaprevir (NS3/4A protease inhibitor), ritonavir (CYP3A inhibitor) fixed dose combination tablets copackaged with dasabuvir (non-nucleoside NS5B palm polymerase inhibitor) tablets.
Factors complicating evaluation of potential DILI with Viekira Pak

- ALT elevations observed in estrogen-containing oral contraceptive DDI trial in healthy volunteers
- Risk of elevations of ALT in females using systemic estrogen containing medications seen in phase 3 trials was higher than overall population (9% vs. 1%)
- Paritaprevirir is a known inhibitor of the bilirubin transporter OATP1B1, which leads to asymptomatic elevations of predominantly indirect bilirubin levels.
- Viekira Pak is combined with Ribavirin for all GT1a subjects and for GT1b subjects with cirrhosis
- Hemolytic anemia caused by ribavirin increases indirect bilirubin levels

Source: Clinical Review available online at Drug@FDA
Summary of Potentially Confounding Issues

- DAAs concentrate and are metabolized in the liver and have various transporter affects (DDIs)
- Patients have various stages of disease and may have very different presentations (asymptomatic to obvious decompensation)
- Genetic factors may play a role for some drugs
- Class affects may be important
Issues that FDA Reviewers Continue to Grapple With!

• How often should patients be monitored for abnormalities of liver biochemistries?

• What level of change warrants modification to the monitoring plan and/or discontinuation (balancing safety with efficacy)?
  – Increase from baseline, or nadir value or ULN?

• Are there “at risk” patients that need enhanced monitoring or should avoid certain drugs/classes?
  – This could include race or other host or viral factors
THANK YOU